introduct
human
host
caus
respiratori
syndrom
name
current
pandem
start
decemb
wuhan
china
rapidli
diffus
throughout
asian
contin
europ
recent
unit
state
predominantli
respiratori
infect
span
mild
involv
upper
respiratori
tract
sever
pneumonia
lead
respiratori
distress
shock
death
diseas
commonli
transmit
hospit
set
healthcar
provid
highest
risk
infect
februari
confirm
chines
healthcar
worker
april
massachusett
gener
hospit
employe
infect
unfortun
current
vaccin
pharmacolog
prophylaxi
decreas
risk
infect
healthcar
provid
thu
safe
prophylact
therapi
reduc
instanc
diseas
healthcar
worker
would
great
benefit
clinic
staff
societi
nitric
oxid
antiinfect
agent
high
concentr
invitro
studi
identifi
signific
activ
pathogen
broadli
resist
antibiot
therapi
bacteria
respons
hospit
acquir
pneumonia
smallsiz
clinic
trial
nitric
oxid
ga
shown
safe
effect
bacteri
colonizationsuperinfect
context
chronic
respiratori
diseas
ga
also
exhibit
antivir
activ
sarscov
invitro
studi
nodonor
compound
snitrosonacteylpenicillamin
increas
surviv
rate
mammalian
cell
infect
sarscov
patient
affect
sar
inhal
decreas
need
oxygen
therapi
ventilatori
support
faster
resolut
chest
xray
abnorm
observ
due
genet
similar
coronavirida
sarscov
might
behav
similarli
ga
exposur
hypothes
high
dose
exogen
inhal
viricid
agent
diseas
dose
ppm
nitric
oxid
found
bactericid
fungicid
viricid
safe
patient
adequ
manag
high
dose
administ
continu
long
period
time
gener
methemoglobinemia
miller
et
al
found
intermitt
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
administr
ppm
cycl
min
antibacteri
effect
safe
administ
hypothes
administr
high
dose
nitric
oxid
prevent
develop
diseas
healthcar
provid
expos
posit
patient
studi
set
singl
center
random
control
parallelarm
clinic
trial
given
absenc
proven
prevent
strategi
healthcar
worker
propos
protocol
interest
center
patient
elig
criteria
inhospit
healthcar
provid
recruit
candid
schedul
work
confirm
patient
least
day
week
exclus
criteria
proven
previou
infect
subsequ
neg
rtpcr
test
pregnanc
known
hemoglobinopathi
known
anemia
inclus
exclus
criteria
summar
tabl
intervent
elig
subject
random
receiv
nitric
oxid
administr
treatment
group
ga
administr
control
group
deliv
daili
session
work
shift
consecut
day
session
last
minut
total
minutesday
subject
see
figur
administ
studi
ga
mouthpiec
connect
breath
circuit
see
figur
circuit
compos
inspiratori
air
oxygen
inlet
expiratori
limb
inspiratori
limb
reservoir
bag
ii
scaveng
contain
soda
lime
minim
concentr
administ
subject
avoid
oxygen
mix
reservoir
bag
lead
format
oneway
valv
posit
nitric
oxid
oxygen
inlet
inspiratori
concentr
continu
monitor
concentr
maintain
ppm
methemoglobin
also
continu
monitor
non
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
invas
dedic
puls
oximet
system
maintain
deliveri
titrat
order
keep
methemoglobin
session
spo
heart
rate
continu
monitor
studi
staff
blood
pressur
measur
noninvas
treatment
valu
record
dedic
paper
data
sheet
specif
start
deliveri
ii
end
deliveri
iii
minut
complet
deliveri
demonstr
decreas
methemoglobin
cessat
ga
deliveri
subject
assign
control
group
receiv
ga
therapi
subject
monitor
day
group
breath
ppm
minut
safe
theoret
risk
breath
includ
follow
pulmonari
edema
methemoglobinemia
hypoxia
hypotens
small
studi
healthi
volunt
frostel
et
al
report
advers
clinic
event
group
inhal
note
averag
baselin
methemoglobin
level
prior
administr
increas
minut
inhal
ppm
statist
signific
although
clinic
irrelev
increas
methemoglobin
level
recent
studi
side
effect
drug
toxic
associ
use
ppm
hour
nitric
oxid
ga
administr
studi
staff
continu
monitor
oxygen
concentr
inhal
ga
peripher
oxygen
satur
spo
continu
monitor
methemoglobin
level
assess
use
noninvas
continu
cooximetri
monitor
methemoglobin
level
rise
progress
reduc
reach
valu
studi
subject
experi
side
effect
suspect
relat
studi
drug
allow
continu
protocol
mask
go
use
studi
subject
investig
awar
studi
alloc
outcom
primari
endpoint
studi
incid
subject
diseas
day
postenrol
defin
infect
confirm
posit
realtim
polymeras
chain
reaction
rtpcr
fever
c
axillari
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
site
c
oral
site
c
rectaltympan
site
cough
short
breath
secondari
endpoint
proport
healthcar
provid
present
posit
real
time
rtpcr
test
day
enrol
proport
healthcar
provid
requir
quarantin
total
number
quarantin
day
two
group
sampl
size
base
avail
data
itali
china
predict
incid
infect
among
healthcar
provid
assum
incid
reduc
inhal
cycl
consid
alpha
level
power
determin
sampl
size
twosid
test
order
account
possibl
dropout
increas
sampl
size
total
subject
group
estim
sampl
size
calcul
use
stata
softwar
recruit
studi
target
popul
healthcar
provid
work
hospit
patient
upon
admiss
first
posit
patient
hospit
unit
healthcar
profession
meet
inclus
exclus
criteria
becom
elig
studi
clinic
staff
unit
adequ
inform
protocol
detail
clinic
care
procedur
interrupt
delay
due
studi
procedur
random
occur
random
alloc
sequenc
gener
computer
random
gener
program
redcap
parallel
alloc
treatment
control
group
occur
ratio
random
stratifi
prespecifi
demograph
condit
eg
sex
age
result
adjust
condit
analysi
phase
specifi
statist
analysi
section
subject
randomli
alloc
either
treatment
group
administr
control
group
administr
data
collect
method
clinic
inform
includ
medic
histori
obtain
particip
interview
collect
studi
variabl
manag
outcom
assessor
use
dedic
subject
file
redcap
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
data
manag
outcom
assessor
treatment
provid
princip
investig
obtain
uniqu
usernam
password
transfer
data
redcap
databas
dedic
studi
data
analyz
follow
intent
treat
analysi
principl
demograph
clinic
data
present
proport
categor
outcom
mean
plu
standard
deviat
median
plu
interquartil
rang
continu
outcom
comparison
group
primari
outcom
made
x
test
fisher
exact
test
categor
variabl
secondari
outcom
analyz
x
test
fisher
exact
test
categor
variabl
ttest
wilcoxon
ranksum
test
continu
variabl
assess
total
number
quarantin
day
normal
distribut
subgroup
analysi
perform
use
multipl
linear
regress
well
logist
cox
regress
model
adjust
age
pulmonari
comorbid
histori
neoplast
diseas
hour
exposit
posit
patient
day
data
safeti
monitor
board
dsmb
pi
dsmb
monitor
advers
event
evalu
data
qualiti
provid
recommend
accordingli
pi
monitor
complianc
safeti
rule
everi
patient
everi
violat
report
dsmb
begin
studi
dsmb
meet
decid
safeti
rule
stop
guidelin
data
safeti
manag
board
dsmb
perform
interim
analysi
superior
th
patient
case
signific
decreas
infect
rate
treat
subject
trial
stop
sign
inform
consent
kept
secur
place
least
year
studi
complet
safeti
data
includ
level
methemoglobin
level
minor
deviat
protocol
minor
advers
reaction
ga
administr
data
review
includ
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
mainten
patient
confidenti
throughout
studi
accord
phrc
polici
advers
event
report
unanticip
problem
involv
risk
subject
princip
investig
report
advers
event
unanticip
problem
dsmb
phrc
within
work
calendar
day
date
investig
first
becom
awar
problem
mild
moder
advers
event
present
progress
report
continu
review
decis
regard
alter
stop
protocol
perform
princip
investig
togeth
data
safeti
manag
board
dsmb
protocol
exit
criteria
acut
worsen
hypotens
defin
decreas
mean
blood
pressur
mmhg
attribut
caus
progress
diseas
hypovolemia
hemorrhag
sepsi
acut
heart
failur
b
sudden
hypoxemia
defin
reduct
peripher
oxygen
satur
spo
basal
valu
